No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Etrolizumab is a monoclonal antibody used to treat inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. It works by targeting a protein called alpha-4-beta-7 integrin, which is involved in the inflammatory process. Etrolizumab is administered intravenously and is approved for use in adults with moderate to severe IBD who have had an inadequate response to conventional therapies. It is also being studied for use in other gastrointestinal diseases such as irritable bowel syndrome and colorectal cancer.
Etrolizumab is a relatively new drug in the gastrointestinal drugs market, but it has shown promise in clinical trials and is gaining traction among physicians and patients. It is seen as a potential alternative to existing treatments, which can have significant side effects.
Companies in the etrolizumab market include Genentech, UCB, and AbbVie. Show Less Read more
